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Summary: There have been significant advances in our understanding of the biology and
classification of endometrial carcinoma, over the last few years, and the new prediction models
proposed for prognostication. To accurately diagnose and stage tumors and apply these
prediction models, it is necessary that there be standardized processing of specimens, and a
common understanding and usage of the diagnostic terminology of endometrial carcinoma.
The International Society of Gynecological Pathologists embarked on an ambitious project to
achieve this goal in 2015. An early step in the process was to collect baseline information on
existing practices with regard to the processing, diagnosis, and reporting of endometrial
carcinomas among the members of the society. This was carried out using a web-based survey
comprising 112 questions. The results are presented herein and reveal areas of uniformity
but also areas of substantial variation among pathologists. The results of the survey assisted
in developing the subsequent recommendations that follow as separate articles in this issue
of the journal with regard to processing, diagnosis, and reporting of endometrial carcinomas.
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Endometrial carcinoma is the sixth most common
malignancy of women worldwide (www.wcrf.org/int/
cancer-facts-figures/data-specific-cancers/endometrial-
cancer-cancer-lining-womb-statistics). It is the most
common gynecologic cancer in the developed world
and the second most common in the developing world
(www.wcrf.org/int/cancer-facts-figures/data-specific-
cancers/endometrial-cancer-cancer-lining-womb-statistics).
Significant advances have been made in our under-
standing of the biology and classification of endome-
trial carcinoma over the past few years, and it is now
expected that the pathologic evaluation of a cancer
resection specimen will inform not only on staging
parameters, but also on accurate subtyping and the
provision of prognostic parameters to accurately direct
management (1).
From the Department of Pathology and Obstetrics and Gynecology,
Yale School of Medicine and the Yale School of Public Health, New
Haven, Connecticut (V.P.); Department of Pathology, Hospital
University Arnau de Vilanova and University de Bellvitge, Irblleida,
Idibell, University of Lleida, Ciberonc, Lleida, Spain (X.M.G.);
Department of Pathology, Massachusetts General Hospital and
Harvard Medical School, Boston, Massachusetts (E.O.); Department
of Pathology, The University of Texas MD Anderson Cancer Center,
Houston, Texas (A.M.); and Department of Pathology, Belfast Health
and Social Care Trust, Belfast, UK (W.G.M.).
Presented in part at the 105th Annual Meeting of the United States
and Canadian Academy of Pathology, March 2016, Seattle, WA.
The authors declare no conflict of interest.
Address correspondence and reprint requests to Vinita Parkash,
MBBS, Department of Pathology, Yale School of Medicine, 333 Cedar
Street, New Haven, CT 06510. E-mail: vinita.parkash@yale.edu.
This is an open access article distributed under the Creative Commons
Attribution License 4.0 (CCBY), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original
work is properly cited.
S3 DOI: 10.1097/PGP.0000000000000515
There have been no large-scale studies documenting
the usual practices for processing, diagnosis, report-
ing, and ancillary testing of endometrial carcinomas
among gynecologic pathologists. The International
Society of Gynecological Pathologists (ISGyP) under-
took a survey of its members, to investigate these
parameters and gather baseline information, and the
results are presented herein.
MATERIALS AND METHODS
Details of the rationale for the project are presented
elsewhere in this issue. A 112-question survey was
designed by the 5 members of the steering committee
appointed by the Board of Directors of the ISGyP
(authors of this paper). The survey was piloted, modified,
and approved by the members of the Board of Directors
and the education committee of the ISGyP. The approved
survey was sent to the membership using the Survey-
Monkey platform (www.surveymonkey.com). The series
of questions explored current practice and perceptions
relating to processing, diagnosing, reporting, and ancillary
testing of endometrial carcinoma. The questions varied in
format, including some with binary responses (Yes/No or
True/False), single-choice responses from a list of
possibilities, and multiple possible selections from a list
of possibilities. For some questions, respondents were
offered the opportunity to expand on their responses.
A link to the survey was e-mailed to all members of
the society. Participants were given a 6-wk deadline to
complete the survey, with 3 reminders sent over that
time period.
Respondents were given the opportunity to identify
themselves and provide e-mail addresses.
They were incentivized to undertake the survey by
indicating that they would be invited to the upcoming
ISGyP consensus conference that was scheduled for
Seattle, WA, USA, in March 2016, to coincide with
the annual United States and Canadian Academy of
Pathology meeting. While demographic information
(eg, country of practice) was requested, the responses
were broadly analyzed as a single cohort, with some
comparisons performed between North American and
European pathologists, the 2 regions with the largest
cohort of respondents.
RESULTS
There were 242 respondents to the survey represent-
ing 47% of the total society membership, with 221
(91.3%) respondents answering all 112 questions.
Respondents came from 30 countries with 51% from
North America, 19% from Europe (41% of these from
the UK), 11% from Asia and Africa, 6% from Oceania,
and 2% from South America. Seventy-six percent of
respondents self-identified as academics and 24% as
pure gynecologic pathologists. The demographics of the
respondents are detailed in Table 1.






















Percentage of respondents diagnosing only biopsy
samples
1
TABLE 2. Responses regarding intraoperative assessment
% Respondents
Parameters assessed at intraoperative
assessment Always Never Sometimes
Grossing performed at intraoperative
assessment
30 39 31
Frozen section performed at
intraoperative assessment
23 32 45
Following numbers only from
respondents performing FS
Size of tumor given at frozen
section
56 44
Adnexa evaluated grossly 89 11
Myometrial invasion reported at
frozen section
93 7








invasion at frozen section
41 59
Cervical involvement assessed at
frozen section
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Responses with regard to intraoperative assessment
(including frozen section examination) are tabulated
in Table 2. The responses demonstrated substantial
variation among pathologists with regard to the use
of intraoperative assessment, with 39% of pathologists
never assessing hysterectomy specimens for endo-
metrial carcinoma intraoperatively. Of those who did
undertake intraoperative assessment, most indicated that
this was carried out either at the surgeon’s request or to
assess staging parameters. There was significant
variability in the number of sections examined
(1–8) and the parameters assessed at intraoperative
assessment, with myometrial invasion being the most
commonly evaluated (93% of respondents).
Responses to the grossing practice questions are
tabulated in Table 3, and they also revealed significant
variability in practice with regard to some parameters.
There was broad agreement with respect to several
parameters such as recording tumor size and location (99%
and 94%, respectively), including fimbrial sections of the
fallopian tube for histologic assessment (95%), submission
of the entire endometrium in resection specimens for
atypical hyperplasia/endometrial intraepithelial neoplasia
(92%), and microscopic evaluation of entire lymph nodes
(95%). However, there was variability in the number of
sections of tumor examined, ranging from 1 to 2 sections
per cm of the entire tumor (responses not shown). There
was significant disagreement in practice with respect to
other parameters, for example, inking of serosa (46%),
evaluating a single section from grossly normal ovaries
(50%), and lymph node assessment (53% not examining
residual fatty tissue and 47% undertaking sentinel node
assessment).
Microscopic variables assessed and reported are
tabulated in Table 4. As a general observation, there
was greater variability in the assessment of microscopic
than gross parameters. International federation of
gynecology and obstetrics (FIGO) grading was used
by 97% of respondents. However, there was variability
in the more granular use of the FIGO grading system,
with 17% of respondents indicating that they assigned
mixed FIGO grades to phenotypically heterogenous
tumors. Reporting of background endometrium and
cervical gland involvement was performed by 92% and
90% of respondents, respectively. There was significant
variability with respect to minimal and necessary criteria to
diagnose high-grade subtypes of endometrial carcinoma
(serous, clear cell, carcinosarcoma, undifferentiated), with
22% to 60% of respondents variably using morphology
alone to histotype tumors. Nine percent of respondents
indicated that they did not report tumor stage in pathology
reports; of those that did, 94% used the FIGO staging
system with or without the TNM stage.
There was also substantial variability in ancillary
testing of endometrial carcinomas, although testing
for mismatch repair protein abnormalities and possi-
ble Lynch syndrome was performed in at least a





Inking of serosa 46
Tissue always taken for molecular studies 33
Uterus always fixed in formalin before
grossing
67
Entire cervix submitted for microscopic
examination
1
Cervical sections taken at 6 and 12
o’clock
81
Vertical sections taken from the lower
uterine section
71
Tumor size recorded 99
Tumor location in uterus recorded 94
Entire endometrium submitted in
hysterectomy for atypical hyperplasia/
EIN
92
Entire adnexa submitted for microscopic
examination
22
Entire adnexa submitted for microscopic
examination if high-grade carcinoma
26
Fimbrial-tubal sections (with or without
nonfimbrial sections) submitted for
microscopic examination
95
Entire grossly normal ovaries submitted
for microscopic examination
13
Single section submitted for microscopic
examination from grossly normal
ovaries
50
Parametrial sections submitted for
microscopic examination
70
Clearing solution always used for lymph
node assessment
2
Clearing solution never used for lymph
node assessment
84
Entire lymph nodes submitted for
microscopic examination
95
Residual fat submitted for microscopic
examination
53
Residual fat never submitted for
microscopic examination
18
No. of nodes per cassette depends on size 83
Sentinel nodes examined 47
Sentinel nodes examined at frozen section
if grossly suspicious
21
Sentinel node protocol used for sentinel
node assessment
75
No. omental sections if gross tumor
involvement present
2–4 (76)
If omentum grossly negative, no. sections
depends on tumor type
Yes (31)




Block key used for pathology report 79
EIN indicates endometrial intraepithelial neoplasia.
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subset of cases by 82% of respondents (Table 5), with
27% of respondents undertaking the studies in all
cases of endometrial carcinoma. Table 6 documents
the parameters used to trigger the aforementioned
testing.
Some variability in practice was apparent, between
North American and European pathologists, as shown in
Table 7. Differences included percentage of pathologists
involved in grossing of specimens, use of intraoperative
assessment, routine use of immunohistochemistry to
histotype tumors, and performing studies to assess
possible Lynch syndrome. North American pathologists
generally used both TNM and FIGO staging systems,
whereas European pathologists favored using only the
FIGO system.
DISCUSSION
Recent years have witnessed an explosive growth in
our understanding of endometrial carcinoma (1). Like
ovarian carcinoma, endometrial carcinoma is not
1 entity, or even 2, as proposed by Bokhman (2), but
comprises at least 4 distinctive molecular subtypes with
differing prognoses (1). Another significant development
has been the identification of endometrial carcinoma as a
common, and often sentinel, tumor in Lynch syndrome,
TABLE 4. Responses regarding microscopic assessment of endometrial carcinomas
Microscopic variables assessed in reporting of uterine carcinoma
FIGO grading system used for endometrioid carcinomas 97%
Nuclear grade used to upgrade endometrioid carcinomas 2%
Mixed FIGO grades for morphologically different areas 17%
Diagnosis of serous carcinoma based on morphology alone 31%
Diagnosis of clear cell carcinoma based on morphology alone 45%
Diagnosis of undifferentiated carcinoma based on morphology alone 22%
Diagnosis of carcinosarcoma based on morphology alone 60%
Extra sections taken before making a diagnosis of undifferentiated carcinoma 17%
Relative ratios of sarcomatous and carcinomatous components reported for carcinosarcoma 42%
Epithelial component classified when diagnosis of carcinosarcoma rendered 80%
Sarcomatous component classified when diagnosis of carcinosarcoma rendered
(heterologous vs. homologous)
93%
Cut-off percentage for minor tumor type in diagnosing mixed carcinoma Variable (%)
Percentage of myometrial invasion reported 51
Absolute depth of myometrial invasion reported 78
Distance of tumor to serosa recorded 59
Patterns of myometrial invasion reported 49
Lower uterine segment involvement reported 87
Morphology of nontumorous endometrium recorded 90
Cervical gland involvement recorded 92
Depth of cervical stromal invasion recorded 60
Lymphovascular invasion determined on histologic examination alone 90
Lymphovascular invasion quantified 50
Pseudovascular invasion reported 16
Distinction made between lymphatic and blood vessel vascular involvement 22
Tumor in vessels (deep myometrium, parametrium, ovarian hilum, etc.) used to upstage tumor in
the absence of tumor outside vascular channels
11
Parametrial involvement reported 68
Tumor involvement of adenomyosis in outer half of myometrium used to upstage tumor 10
Tumor considered stage IA if deep invasion from focus of adenomyosis is present 55
Free floating intraluminal tubal tumor used to upstage disease 5
Keratin granulomas used to upstage tumors 2
Peritoneal washings routinely examined 85
If washings positive, correlation made with other pathologic features and clinical history
(use of intrauterine balloon manipulator)
44
Lymph node counts reported based on gross assessment 4
Lymph node counts reported based on microscopic assessment 31
Largest metastatic focus in lymph node measured 45
Isolated tumor cells in lymph node reported 65
Extranodal extension reported routinely 75
Pathologic staging stated in report 91
Classification system used for precursor of endometrioid carcinoma EIN (13%), WHO 2014 (71%),
WHO 2003 (16%)
Comments: questions were not asked regarding parameters, which are essential for staging, for example, cervical stromal involvement,
adnexal involvement.
EIN indicates endometrial intraepithelial neoplasia; WHO, World Health Organization.
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one of the most common hereditary cancer syndromes.
These discoveries have led to recommendations from
clinical societies for extended reporting of prognostic
factors and for routine screening of endometrial carcino-
mas for mismatch repair protein abnormalities (3).
However, the impact of these advances on the practice
of specialist gynecologic pathologists around the world is
unknown. The ISGyP therefore undertook a web-based
survey to document current practice patterns before
convening a consensus conference and issuing guidelines
for the diagnoses, reporting, and ancillary testing of
endometrial carcinoma.
The results of our survey show certain consistent
practices among gynecologic pathologists worldwide. For
example, at grossing, recording tumor size and site,
examination of the entire endometrium in resection
specimens for atypical hyperplasia/endometrial intra-
epithelial neoplasia, and assessment of the fimbrial end
of the fallopian tube appear embedded as routine
practice. At microscopic assessment, reporting of tumor
grade, pathologic stage, documentation of depth of
myometrial invasion, assessment of cervical glandular
involvement, and lymphovascular space invasion are
near universal practices. There is also widespread
acceptance and utilization of the FIGO grading and
staging systems. That said, there are also areas of
significant practice variability, including the number of
sections of tumor, adnexal tissue, omentum, and lymph
nodes examined. While FIGO grading is used universally
for reporting, the actual usage shows some variability,
with 17% of respondents using mixed grading for
phenotypically heterogenous endometrioid carcinomas.
Histotyping of nonendometrioid carcinomas, not unex-
pectedly, seems to be a particularly challenging area for
gynecologic pathologists, with morphologic criteria alone
being used for subtyping in 22% to 60% of cases,
depending on the favored subtype, with ancillary studies
being used variably. This raises some concerns about the
consistency of diagnostic criteria across studies and
institutions, especially as several studies have shown
TABLE 5. Responses regarding ancillary testing of
endometrial carcinomas
Studies undertaken in some cases 82%
Studies undertaken in all endometrial
carcinoma cases
27%
Studies undertaken in all endometrioid
carcinoma cases
8%
Immunohistochemical studies done for Lynch
syndrome assessment
94% (12% use 2
antibodies)
Lynch syndrome studies undertaken in all
endometrial carcinomas
26%
Entire endometrium examined in prophylactic
hysterectomy for Lynch syndrome
50%
Entire adnexa examined in prophylactic
hysterectomy for Lynch syndrome
57%
Methylation studies performed if MLH1/
PMS2 loss on immunohistochemistry
56%
Molecular analysis never performed 26%
Molecular analysis always performed 9%
Hormone receptor staining always performed 17%
If hormone receptor staining performed, is it
used for prediction of response to hormone
therapy
26%
Ploidy studies performed 2%
Molecular analysis for synchronous uterine
and ovarian carcinomas performed
7%
TABLE 6. Parameters used to trigger testing for possible
Lynch syndrome
Criterion for possible Lynch syndrome testing % Respondents
Age based 41
Personal and family history based 42
Morphology and topography based 33
Combination 42
At request of clinician 70
Other (please specify) 11






Percentage of pathologists involved











Horizontal sectioning of lower
uterine segment
23 53
Sentinel nodes assessed 58 31
Frozen section performed for
sentinel nodes
29 53
Morphology alone used for
diagnosis of serous carcinoma
8 37
Morphology alone used for
diagnosis of clear cell carcinoma
7 29













Distance to serosa recorded (mm) 47 73





undertaken in all endometrial
carcinomas
42 0
Methylation studies performed for
loss of MLH1/PMS2
66 33
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significant variability in the classification and typing of
high-grade endometrial carcinoma, even among expert
gynecologic pathologists (4–6).
Similarly, there is substantial variability with respect to
assessment of risk for Lynch syndrome, with only a subset
of pathologists performing these studies on all cases of
endometrial adenocarcinomas (27%). Immunohistochem-
istry is the favored modality for initial investigation.
Our study also documents some practice differences
between North American and European pathologists.
In North America, there is a greater use of pathology
assistants for grossing of specimens, greater use of
intraoperative assessment and frozen sections, and an
increased propensity to use ancillary studies for
subtyping. North American pathologists are also
more likely to report a TNM stage than European
pathologists. This is not surprising, as in the United
States, use of the American Joint Committee on
Cancer version of TNM is required for College of
Surgeons Cancer Center accreditation, NCCN Clin-
ical decision guidelines implementation, and for the
College of American Pathologists accreditation.
A drawback of this survey is that it was only sent to
the members of ISGyP, and, as such, the results are
skewed toward the practices of specialist gynecologic
pathologists at academic centers. In spite of a
relatively high participation rate of 47%, the possi-
bility of a self-selection bias cannot be excluded. As
always, reporting of the expected ideal rather than the
practiced behavior may have influenced the results.
CONCLUSIONS
The survey shows areas of concordance and variability
in practice among gynecologic pathologists worldwide in
dealing with endometrial carcinoma specimens.
The results of this survey helped identify areas in
need of consensus to standardize processing, diag-
nostic and reporting criteria, and ancillary testing of
endometrial carcinoma. These results informed the
deliberations of the Endometrial Carcinoma Project
subcommittees for the International Society of Gyne-
cological Pathology. The remaining articles in this
journal describe the process and the recommendations
that emerged from that project.
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